NFKB1 and cancer: Because the hyperactivity of NF‐κB is considered one of the ‘hallmarks’ of cancer, and its role in chemoresistance is gaining recognition, substantial efforts within the recent decade have been made toward development of NF‐κB inhibitors (DiDonato et al., 2012; Gilmore and Herscovitch, 2006).